Avanos Medical Inc
NYSE:AVNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Avanos Medical Inc
NYSE:AVNS
|
US |
|
Sumitomo Forestry Co Ltd
TSE:1911
|
JP |
|
NSI NV
AEX:NSI
|
NL |
Avanos Medical Inc
Avanos Medical, Inc. operates as a medical technology company. The company is headquartered in Alpharetta, Georgia and currently employs 4,555 full-time employees. The company went IPO on 2014-10-21. The firm develops, manufactures and markets solutions in approximately 90 countries. The company provides a portfolio of product offerings focused on chronic care and pain management to improve patient outcomes. Chronic care is a portfolio of products, which include digestive health products, such as its Mic-Key enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as its closed airway suction systems and other airway management devices under the Ballard, Microcuff and Endoclear brands. Pain management is a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and Interventional pain solutions, which provides pain relieving therapies, such as its Coolief pain therapy.
Avanos Medical, Inc. operates as a medical technology company. The company is headquartered in Alpharetta, Georgia and currently employs 4,555 full-time employees. The company went IPO on 2014-10-21. The firm develops, manufactures and markets solutions in approximately 90 countries. The company provides a portfolio of product offerings focused on chronic care and pain management to improve patient outcomes. Chronic care is a portfolio of products, which include digestive health products, such as its Mic-Key enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as its closed airway suction systems and other airway management devices under the Ballard, Microcuff and Endoclear brands. Pain management is a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and Interventional pain solutions, which provides pain relieving therapies, such as its Coolief pain therapy.
Revenue: Avanos reported full-year net sales of $701 million, exceeding the revised guidance after Q3.
Earnings: Adjusted diluted EPS reached $0.94 for the year, finishing at the high end of the revised range.
Segment Growth: Specialty Nutrition Systems grew over 8% organically, outperforming the market, while Pain Management & Recovery normalized organic sales increased 2.3%.
Tariff Impact: Tariffs significantly affected profitability in 2025, but mitigation strategies are on track; a $30 million tariff impact is anticipated in 2026, with major relief expected after exiting China by June.
Guidance: 2026 net sales are expected in the range of $700–$720 million, with adjusted diluted EPS projected between $0.90 and $1.10.
Portfolio Moves: Avanos divested its hyaluronic acid and IV therapy businesses, acquired Nexus Medical, and realigned the GAME READY business to enhance profitability.
Operating Efficiency: Cost-saving initiatives and operating efficiencies drove margin improvements and are expected to support further progress in 2026.
